Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Caladrius Biosciences Q2 EPS $(0.10) Beats $(0.14) Estimate

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 68.75 percent increase over losses of $(0.32) per share
byBill Haddad
August 5, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 68.75 percent increase over losses of $(0.32) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

This Week’s Scheduled IPOs

By Benzinga Insights
Today, 3:35 AM
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

NAVA